Author:
Irimu Grace,Okwaro Ferdinand,Coleman Jesse,Waiyego Mary,Murila Florence,Chomba Dorothy,Parsimei Millicent,Shitote Cynthia,Ochieng Roseline,Shah Jasmit,Ogero Morris,Ginsburg Amy Sarah,Ansermino J. Mark,Macharia William
Abstract
Abstract
Background
Apnoea of prematurity (AOP) is a common condition among preterm infants. Methylxanthines, such as caffeine and aminophylline/theophylline, can help prevent and treat AOP. Due to its physiological benefits and fewer side effects, caffeine citrate is recommended for the prevention and treatment of AOP. However, caffeine citrate is not available in most resource-constrained settings (RCS) due to its high cost. Challenges in RCS using caffeine citrate to prevent AOP include identifying eligible preterm infants where gestational age is not always known and the capability for continuous monitoring of vital signs to readily identify apnoea. We aim to develop an evidence-based care bundle that includes caffeine citrate to prevent and manage AOP in tertiary healthcare facilities in Kenya.
Methods
This protocol details a prospective mixed-methods clinical feasibility study on using caffeine citrate to manage apnoea of prematurity in a single facility tertiary-care newborn unit (NBU) in Nairobi, Kenya. This study will include a 4-month formative research phase followed by the development of an AOP clinical-care-bundle prototype over 2 months. In the subsequent 4 months, implementation and improvement of the clinical-care-bundle prototype will be undertaken. The baseline data will provide contextualised insights on care practices within the NBU that will inform the development of a context-sensitive AOP clinical-care-bundle prototype. The clinical care bundle will be tested and refined further during an implementation phase of the quality improvement initiative using a PDSA framework underpinned by quantitative and qualitative clinical audits and stakeholders’ engagement.
The quantitative component will include all neonates born at gestation age < 34 weeks and any neonate prescribed aminophylline or caffeine citrate admitted to the NBU during the study period.
Discussion
There is a need to develop evidence-based and context-sensitive clinical practice guidelines to standardise and improve the management of AOP in RCS. Concerns requiring resolution in implementing such guidelines include diagnosis of apnoea, optimal timing, dosing and administration of caffeine citrate, standardisation of monitoring devices and alarm limits, and discharge protocols. We aim to provide a feasible standardised clinical care bundle for managing AOP in low and middle-income settings.
Funder
Bill and Melinda Gates Foundation
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Irimu G, Aluvaala J, Malla L, Omoke S, Ogero M, Mbevi G, et al. Neonatal mortality in Kenyan hospitals: a multisite, retrospective, cohort study. BMJ Glob Health. 2021;6(5): e004475.
2. Henderson-Smart D. The effect of gestational age on the incidence and duration of recurrent apnoea in newborn babies. J Paediatr Child Health. 1981;17(4):273–6.
3. Barrington K, Finer N. The natural history of the appearance of apnea of prematurity. Pediatr Res. 1991;29(4):372–5.
4. Miao Y, Zhou Y, Zhao S, Liu W, Wang A, Zhang Y, et al. Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: a systematic review and meta-analysis. PLoS ONE. 2022;17(9): e0274882.
5. Zhang C-Y, Liu DJ, Hua S-D, Guo S, Li X-Y, Zhang B, et al. Caffeine versus aminophylline in combination with oxygen therapy for apnea of prematurity: a retrospective cohort study. Exp Ther Med. 2020;20(5):1-.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献